Evidence map›Paper›PMID 35578088›Full record

ReviewBreast cancer (Tokyo, Japan)2022

Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.

Partha Roy, Srija Sur, Suvadra Das, Wong Tin Wui

Abstract readReview
PubMed Publisher
In one paragraph

Review in Breast cancer (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Partha RoyDepartment of Pharmaceutical Technology, Adamas University, Kolkata, India. partharoy2502@gmail.com.ORCID http://orcid.org/0000-0002-9641-6136
Srija SurDepartment of Pharmaceutical Technology, Adamas University, Kolkata, India.
Suvadra DasBasic Science and Humanities Department, University of Engineering and Management, Kolkata, India.
Wong Tin WuiNon-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE, UniversitiTeknologi MARA, Selangor, Malaysia.
Adamas University · INUniversiti Teknologi MARA · MYUniversity of Engineering & Management · IN

Funding

Science and Engineering Research Board IMRC/AISTDF/CRD/20191000133
6 · The paper itself

Abstract

Breast cancer is the most common malignancy in women and is rated among one of the three common malignancies worldwide in combination with colon and lung cancer. The escalating mortality rate of breast cancer patients has captivated the attention of the present-day researchers to come up with new management options. According to WHO, early detection, timely diagnosis and comprehensive breast cancer management are the three cornerstones for controlling breast cancer incidences per year. Multidisciplinary theragnostic approaches for simultaneous diagnosis and treatment of breast cancer have further enriched the therapeutic arsenal. Imaging and biopsy play a significant role in the diagnosis of breast cancer. The treatment plan mostly initiates with general surgery or radiation therapy followed up with adjuvant and/or neoadjuvant therapy. Conventional chemotherapeutics in breast cancer suffer from toxicity and lack of site specificity. Bio-safe gold nanoparticles hold sufficient promise for bridging this gap. Diverse phytochemicals-based synthesis routes to arrive at nano-dimensional gold with spotlight on reaction mechanisms, reaction variables, specific advantages, toxicity and their influence in breast cancer conditions are the focus of this work. This review marks the first attempt to explore the potential of phytochemical-derived nano-gold in breast cancer treatment.

Indexed as

Breast NeoplasmsMetal NanoparticlesBreastFemaleGoldHumansPhytochemicalsGoldPhytochemicalsBio-safeBreast cancerGold nanoparticlePhytochemicalsTheragnostic

Identifiers

PMID35578088
OpenAlexW4280516285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.